Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Allarity Therapeutics, Inc. (ALLR)

Allarity Therapeutics ends $6.0 million stock purchase deal with Tumim Stone Capital

Neutral Impact 2 of 5 financing Written later

Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital LLC on October 28, 2026, which had allowed the company to sell up to $6.0 million of newly issued common stock to Tumim at its discretion. The company said it chose to end the agreement to pursue alternative financing arrangements, and it will not sell further shares to Tumim under it.

Key points

  • Agreement dated January 28, 2026, allowed sales of up to $6.0 million of newly issued common stock to Tumim.
  • Termination effective October 28, 2026; the company says no early termination penalty is payable.
  • Indemnification and certain expense obligations survive termination.
  • The company plans to pursue alternative financing arrangements; the filing does not name them.

The filing

CompanyAllarity Therapeutics, Inc. (ALLR)
Form8-K, current report
Filed with the SECOct 30, 2026, 4:05 PM ET
Accession number0001213900-26-114380

Items reported: 1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.